Given the importance of the ERK1/2 pathway in the progression of prostate cancer, the molecules involved in regulation of this pathway are thought to be appealing targets for prostate cancer therapeutics (34, 35). This evidence concerns the gene MAPK3 and Familial prostate cancer.